Reopening the Brain’s Window of Plasticity
How flickering light triggers the brain’s own immune cells to dismantle the molecular brakes on learning and recovery. Based on: Venturino et al., Cell Reports,…
How flickering light triggers the brain’s own immune cells to dismantle the molecular brakes on learning and recovery. Based on: Venturino et al., Cell Reports,…
Syntropic Honored at the U.S. Embassy in Vienna Credits: Vitor Goncalves. Syntropic wins 1st prize at the national preliminary round for the SelectUSA Investment Summit,…
Syntropic Medical completes Phase IIa LUX study of HAVEN™, an investigational, non-invasive light-based approach for depression Early clinical evaluation in Brazil supports safety and tolerability…
By Momcilo Nikolic 20.10.2025 Syntropic: Klosterneuburger MedTech startet Kooperationen in Brasilien und New York Das NÖ-MedTech-Startup Syntropic hat abseits medialer Aufmerksamkeit erste klinische Erfolge gefeiert…
Syntropic Medical publishes first–in–human study on novel light therapy technology in PLOS One Vienna, 7. October 2025 On October 7, 2025, Syntropic Medical has announced…
Best of Biotech 2025 Winner Credit: © Vogus / Wolfgang Voglhuber Syntropic Medical has been awarded Best of Biotech 2025 in the Medtech Start-up category….
Vienna, Austria, September 5, 2025 Syntropic initiates first patient stimulation in home-based depression clinical trial On September 5, 2025, the company reached a key clinical…
Vienna, Austria, August 4, 2025 Syntropic Medical receives IRB approval for new home-based light therapy clinical trial On July 15, 2025, Syntropic Medical reached a…
Vienna, Austria, July 23, 2025 Syntropic Medical completes first patient stimulation in depression clinical trial On May 5, 2025, Syntropic Medical completed the first full…
Troy Dale Strategic Advisor and Investor Troy Dale, who originally trained as a Pharmacologist has over 30 years of experience in the pharmaceutical industry, spanning…